Serial anti-VEGF injections could increase IOP

Article

Administering serial antivascular endothelial growth factor (VEGF) injections could lead to increased intraocular pressure (IOP) and may require glaucoma therapy

Administering serial antivascular endothelial growth factor (VEGF) injections could lead to increased intraocular pressure (IOP) and may require glaucoma therapy, according to the Journal of Glaucoma.

Dr Joseph J. Tseng, Vitreous Retina Macula Consultants of New York, New York, USA, led a investigation consisting of 25 eyes of 23 patients with neovascular age-related macular degeneration (AMD). All patients has increased IOP whilst receiving interval doses of ranibizumab or bevacizumab. All patients had no previous IOP elevations and tolerated multiple anti-VEGF injections.

Patients received a mean of 20 anti-VEGF injections and the mean IOP was 29.8 mmHg, compared to a mean baseline of 16.9 mmHg. The highest IOP recorded was 35.8 mmHg.

Of the patients included in the study, 23 of 25 cases underwent IOP management and two cases switched from regular anti-VEGF doses to an optical coherence tomography-guided variable regimen.

The elevation in IOP can occur even if the patient previously tolerated multiple anti-VEGF injections. The results warrant further investigation into the link between anti-VEGF therapy and IOP.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.